

“Small Molecule Activators of Pyruvate Kinase,” filed April 8, 2011 [HHS Ref. No. E-326-2008/0-US-07]; Australian National Application No. 2009303335, entitled “Small Molecule Activators of Pyruvate Kinase,” filed October 9, 2010 [HHS Ref. No. E-326-2008/0-AU-03]; Canadian National Application, entitled “Small Molecule Activators of Pyruvate Kinase,” filing date pending [HHS Ref. No. E-326-2008/0-CA-04]; Japanese National Application, entitled “Small Molecule Activators of Pyruvate Kinase,” filing date pending [HHS Ref. No. E-326-2008/0-JP-06]; U.S. Provisional Patent Application No. 61/329,158, entitled “Pyruvate Kinase M2 Activators for the Treatment of Cancer,” filed April 29, 2010, now abandoned [HHS Ref. No. E-120-2010/0-US-01]; and PCT Application PCT/US2011/033852 entitled “Pyruvate Kinase M2 Activators for the Treatment of Cancer,” filed April 26, 2011 [HHS Ref. No. E-120-2010/0-PCT-02] to Forma Therapeutics, Inc., having an office at 790 Memorial Drive, Cambridge, MA 02139. The patent rights in these inventions have been assigned to the United States of America.

The prospective exclusive license territory may be worldwide, and the field of use may be limited to the use of PKM2 activators as human therapeutics for the treatment of cancer.

**DATES:** Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before September 7, 2011 will be considered.

**ADDRESSES:** Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Steven Standley, PhD, Licensing and Patenting Manager, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-4074; Facsimile: (301) 402-0220; E-mail: [sstand@od.nih.gov](mailto:sstand@od.nih.gov).

**SUPPLEMENTARY INFORMATION:** The fetal form of Pyruvate Kinase, called PKM2, is expressed in all cancer cells and imparts an important metabolic change on cancer cells which allows them to grow and divide rapidly. That is, PKM2 is normally inactive, which allows cancer cells to create an abundance of molecules for cellular growth and division. The products and methods sought in the prospective license activate PKM2 and result in inhibition of tumor development.

This invention relates to products and methods of administering PKM2 activators of various types and methods

of treating cancer and diseases susceptible to PKM2 activators.

The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within thirty (30) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: August 2, 2011.

**Richard U. Rodriguez,**

*Director, Division of Technology Development & Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 2011-20003 Filed 8-5-11; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### Fiscal Year (FY) 2011 Funding Opportunity

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS.

**ACTION:** Notice of intent to award a Single Source Grant to the Health Service Center, Inc., Anniston, AL.

**SUMMARY:** This notice is to inform the public that the Substance Abuse and Mental Health Services Administration (SAMHSA) intends to award approximately \$300,000 (total costs) per year for up to four years to the Health Service Center, Inc., Anniston, AL. This is not a formal request for applications. Assistance will be provided only to the Health Service Center, Inc., Anniston, AL, based on the receipt of a satisfactory application that is approved by an independent review group.

*Funding Opportunity Title:* SP-11-005.

Catalog of Federal Domestic Assistance (CFDA) Number: 93.243

**Authority:** Section 516 of the Public Health Service Act, as amended.

*Justification:* Only the Health Service Center, Inc., Anniston, AL, is eligible to

apply. The Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Prevention (CSAP) is seeking to award a single source grant to the Health Service Center, Inc., Anniston, AL, for the Capacity Building Initiative (CBI). CBI is one of CSAP's Minority AIDS Initiative (MAI) programs. The purpose of the MAI is to provide substance abuse and HIV prevention services to at-risk minority populations in communities disproportionately affected by HIV/AIDS. The purpose of the CBI program is to support an array of activities to assist grantees in building a solid foundation for delivering and sustaining quality and accessible state of the science substance abuse and HIV prevention services. Specifically, the program aims to engage colleges, universities and community-level domestic public and private non-profit entities to prevent and reduce the onset of SA and transmission of HIV/AIDS among at-risk racial/ethnic minority young adults, ages 18-24.

The Health Service Center, Inc., Anniston, AL, was funded under the SP-10-004 CBI Initiative in FY 2010. At that time, the Health Services Center, Inc. proposed a 5-year program in their grant application, but inadvertently requested one year of funding rather than the full program funding period of 5 years. It was clear from language in the original application (which specifically referred to individual years of the program, and numbers served throughout the project) that the grantee intended to apply for funding for the full five years. The purpose of this sole source award is to fund the 4 out years of the 5 year cooperative agreement awarded under the initial announcement. SAMHSA will not accept an application from any other entity.

#### FOR FURTHER INFORMATION CONTACT:

Shelly Hara, Substance Abuse and Mental Health Services Administration, 1 Choke Cherry Road, Room 8-1095, Rockville, MD 20857; *telephone:* (240) 276-2321; *E-mail:* [shelly.hara@samhsa.hhs.gov](mailto:shelly.hara@samhsa.hhs.gov).

**Cathy Friedman,**

*Public Health Analyst, SAMHSA .*

[FR Doc. 2011-19965 Filed 8-5-11; 8:45 am]

**BILLING CODE 4162-20-P**